Literature DB >> 28085498

Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Neil J Kelly1, Josiah E Radder1, Jeffrey J Baust2, Christine L Burton1, Yen-Chun Lai1,2, Karin C Potoka1,3, Brittani A Agostini1, John P Wood1, Timothy N Bachman2, Rebecca R Vanderpool2, Nadine Dandachi1, Adriana S Leme1, Alyssa D Gregory1, Alison Morris1, Ana L Mora1,2, Mark T Gladwin1,2, Steven D Shapiro1.   

Abstract

Pulmonary hypertension (PH) is associated with features of obesity and metabolic syndrome that translate to the induction of PH by chronic high-fat diet (HFD) in some inbred mouse strains. We conducted a genome-wide association study (GWAS) to identify candidate genes associated with susceptibility to HFD-induced PH. Mice from 36 inbred and wild-derived strains were fed with regular diet or HFD for 20 weeks beginning at 6-12 weeks of age, after which right ventricular (RV) and left ventricular (LV) end-systolic pressure (ESP) and maximum pressure (MaxP) were measured by cardiac catheterization. We tested for association of RV MaxP and RV ESP and identified genomic regions enriched with nominal associations to both of these phenotypes. We excluded genomic regions if they were also associated with LV MaxP, LV ESP, or body weight. Genes within significant regions were scored based on the shortest-path betweenness centrality, a measure of network connectivity, of their human orthologs in a gene interaction network of human PH-related genes. WSB/EiJ, NON/ShiLtJ, and AKR/J mice had the largest increases in RV MaxP after high-fat feeding. Network-based scoring of GWAS candidates identified epidermal growth factor receptor (Egfr) as having the highest shortest-path betweenness centrality of GWAS candidates. Expression studies of lung homogenate showed that EGFR expression is increased in the AKR/J strain, which developed a significant increase in RV MaxP after high-fat feeding as compared with C57BL/6J, which did not. Our combined GWAS and network-based approach adds evidence for a role for Egfr in murine PH.

Entities:  

Keywords:  genome-wide association study; metabolic syndrome; pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28085498      PMCID: PMC5449510          DOI: 10.1165/rcmb.2016-0176OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  43 in total

1.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 2.  The genetics of pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

3.  Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Archana Kangath; Ning Qu; Saurabh Aggarwal; Shruti Sharma; Julin Desai; Taylor Fields; Britta Ludewig; Jason X-Y Yuan; Danny Jonigk; Stephen M Black
Journal:  Free Radic Biol Med       Date:  2016-02-27       Impact factor: 7.376

4.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

5.  Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension.

Authors:  Emma K Larkin; John H Newman; Eric D Austin; Anna R Hemnes; Lisa Wheeler; Ivan M Robbins; James D West; John A Phillips; Rizwan Hamid; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2012-08-23       Impact factor: 21.405

6.  Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension.

Authors:  C Agard; M Rolli-Derkinderen; E Dumas-de-La-Roque; M Rio; C Sagan; J P Savineau; G Loirand; P Pacaud
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

Review 7.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Florent Soubrier; Wendy K Chung; Rajiv Machado; Ekkehard Grünig; Micheala Aldred; Mark Geraci; James E Loyd; C Gregory Elliott; Richard C Trembath; John H Newman; Marc Humbert
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth.

Authors:  P L Jones; J Crack; M Rabinovitch
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

9.  The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease.

Authors:  Janan T Eppig; Judith A Blake; Carol J Bult; James A Kadin; Joel E Richardson
Journal:  Nucleic Acids Res       Date:  2014-10-27       Impact factor: 16.971

10.  Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.

Authors:  Sergio E Baranzini; Nicholas W Galwey; Joanne Wang; Pouya Khankhanian; Raija Lindberg; Daniel Pelletier; Wen Wu; Bernard M J Uitdehaag; Ludwig Kappos; Chris H Polman; Paul M Matthews; Stephen L Hauser; Rachel A Gibson; Jorge R Oksenberg; Michael R Barnes
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

View more
  13 in total

1.  Adenoviral transduction of EGFR into pregnancy-adapted uterine artery endothelial cells remaps growth factor induction of endothelial dysfunction.

Authors:  Luca Clemente; Derek S Boeldt; Mary A Grummer; Mayu Morita; Terry K Morgan; Greg J Wiepz; Paul J Bertics; Ian M Bird
Journal:  Mol Cell Endocrinol       Date:  2019-09-21       Impact factor: 4.102

2.  Finally, Progress in Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction.

Authors:  Wassim H Fares; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

3.  Variable Susceptibility to Cigarette Smoke-Induced Emphysema in 34 Inbred Strains of Mice Implicates Abi3bp in Emphysema Susceptibility.

Authors:  Josiah E Radder; Alyssa D Gregory; Adriana S Leme; Michael H Cho; Yanxia Chu; Neil J Kelly; Per Bakke; Amund Gulsvik; Augusto A Litonjua; David Sparrow; Terri H Beaty; James D Crapo; Edwin K Silverman; Yingze Zhang; Annerose Berndt; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

Review 4.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 5.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

6.  Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction.

Authors:  Qingqing Meng; Yen-Chun Lai; Neil J Kelly; Marta Bueno; Jeffrey J Baust; Timothy N Bachman; Dmitry Goncharov; Rebecca R Vanderpool; Josiah E Radder; Jian Hu; Elena Goncharova; Alison M Morris; Ana L Mora; Steven D Shapiro; Mark T Gladwin
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

Review 7.  Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors:  Nicholas E King; Evan Brittain
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

8.  A Review of Transcriptome Analysis in Pulmonary Vascular Diseases.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Methods Mol Biol       Date:  2018

Review 9.  Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.

Authors:  Sanjiv J Shah; Barry A Borlaug; Dalane W Kitzman; Andrew D McCulloch; Burns C Blaxall; Rajiv Agarwal; Julio A Chirinos; Sheila Collins; Rahul C Deo; Mark T Gladwin; Henk Granzier; Scott L Hummel; David A Kass; Margaret M Redfield; Flora Sam; Thomas J Wang; Patrice Desvigne-Nickens; Bishow B Adhikari
Journal:  Circulation       Date:  2020-03-23       Impact factor: 29.690

10.  Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Authors:  Longfei Wang; Gunner Halliday; Joshua R Huot; Taijyu Satoh; Jeffrey J Baust; Amanda Fisher; Todd Cook; Jian Hu; Theodore Avolio; Dmitry A Goncharov; Yang Bai; Rebecca R Vanderpool; Robert V Considine; Andrea Bonetto; Jiangning Tan; Timothy N Bachman; Andrea Sebastiani; Charles F McTiernan; Ana L Mora; Roberto F Machado; Elena A Goncharova; Mark T Gladwin; Yen-Chun Lai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.